Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition.

[1]  J. Tabernero,et al.  Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Turley,et al.  A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys. , 2020, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  Gregory D Rak,et al.  Intermittent dosing of the transforming growth factor beta receptor 1 inhibitor, BMS‐986260, mitigates class‐based cardiovascular toxicity in dogs but not rats , 2020, Journal of applied toxicology : JAT.

[4]  K. Pradhan,et al.  Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes , 2019, Clinical Cancer Research.

[5]  M. Yoshikawa,et al.  Small-scale panel comprising diverse gene family targets to evaluate compound promiscuity. , 2019, Chemical research in toxicology.

[6]  M. Yokoyama,et al.  Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors. , 2019, Pulmonary pharmacology & therapeutics.

[7]  Xuedong Zhou,et al.  Transforming growth factor-β in stem cells and tissue homeostasis , 2018, Bone Research.

[8]  J. Zhang,et al.  Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats , 2016, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[9]  Yi-Ping Li,et al.  TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease , 2016, Bone Research.

[10]  R. Chambers,et al.  The anti-fibrotic effect of inhibition of TGFβ-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent γ-herpesvirus infection , 2015, Disease Models & Mechanisms.

[11]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[12]  M. Abdullah,et al.  Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis. , 2015, Molecular medicine reports.

[13]  M. Pirmohamed,et al.  Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury , 2015, British journal of pharmacology.

[14]  J. Baselga,et al.  Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer , 2014, Investigational New Drugs.

[15]  J. Baselga,et al.  Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study , 2014, Cardiovascular Toxicology.

[16]  J. Baselga,et al.  First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma , 2014, Clinical Cancer Research.

[17]  Pirjo Spuul,et al.  ALK5 and ALK1 Play Antagonistic Roles in Transforming Growth Factor β-Induced Podosome Formation in Aortic Endothelial Cells , 2014, Molecular and Cellular Biology.

[18]  K. Credille,et al.  Nonclinical Safety Evaluation of a Transforming Growth Factor β Receptor I Kinase Inhibitor in Fischer 344 Rats and Beagle Dogs , 2014 .

[19]  M. Anderton,et al.  Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.

[20]  C. Elangbam,et al.  Drug-induced Valvulopathy: An Update , 2010, Toxicologic pathology.

[21]  K. Garber.  Companies waver in efforts to target transforming growth factor beta in cancer. , 2009, Journal of the National Cancer Institute.

[22]  A. Kulkarni,et al.  Critical roles of the TGF-beta type I receptor ALK5 in perichondrial formation and function, cartilage integrity, and osteoblast differentiation during growth plate development. , 2009, Developmental biology.

[23]  M. Goumans,et al.  Poor vessel formation in embryos from knock-in mice expressing ALK5 with L45 loop mutation defective in Smad activation , 2009, Laboratory Investigation.

[24]  R. Schwartz,et al.  Signaling via the Tgf-beta type I receptor Alk5 in heart development. , 2008, Developmental biology.

[25]  D. J. Alexander,et al.  Association of Inhalation Toxicologists (AIT) Working Party Recommendation for Standard Delivered Dose Calculation and Expression in Non-Clinical Aerosol Inhalation Toxicology Studies with Pharmaceuticals , 2008 .

[26]  M. Goumans,et al.  Compensatory signalling induced in the yolk sac vasculature by deletion of TGFβ receptors in mice , 2007, Journal of Cell Science.

[27]  H. Kikkawa,et al.  Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. , 2007, Experimental and molecular pathology.

[28]  R. Mirabile,et al.  Inhibition of ALK5 Signaling Induces Physeal Dysplasia in Rats , 2007, Toxicologic pathology.

[29]  M. Kolb,et al.  Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. , 2005, American journal of respiratory and critical care medicine.

[30]  A. Roberts,et al.  SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. , 2004, Molecular pharmacology.

[31]  Jonas Larsson,et al.  Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. , 2003, Molecular cell.

[32]  C. Lisboa,et al.  Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. , 2001, American journal of respiratory and critical care medicine.

[33]  M. Goumans,et al.  Abnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice , 2001, The EMBO journal.

[34]  T. Mak,et al.  Normal B lymphocyte development but impaired T cell maturation in CD45-Exon6 protein tyrosine phosphatase-deficient mice , 1993, Cell.

[35]  A. Wakeham,et al.  Profound block in thymocyte development in mice lacking p56lck , 1992, Nature.